MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejim.2023.01.029

Медицинская библиотека · European journal of internal medicine · 2023

Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.

Xie Zhi-Qin, Li Hong-Xia, Wang Bing-Kun, Yang Zhao-Ming, Zhang Zi-Yu, Tan Wen-Liang, Li Wen-Xin, Wang Qing-Bin, Yang Lei, Zhuang Hong-Kai, Tang Chen-Wei, Shang Chang-Zhen, Chen Ya-Jin

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Given the escalating epidemic of obesity and diabetes coupled with redefined diagnostic criteria, it is critical to identify the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD). We sought to determine the prevalence and mortality outcomes of MAFLD subtypes based on diagnostic criteria in the USA over the past three decades.

METHODS

Eleven cycles of the National Health and Nutrition Examination Surveys (NHANES; 1988-1994 and 1999-2020) were used, and 72,224 participants were included. MAFLD was defined according to the 2020 International Expert Consensus. Based on diagnostic criteria and risk factors, MAFLD was categorized into seven subtypes: type 1 (obesity subtype), 2 (metabolic unhealthy subtype), 3 (diabetes subtype), 4 (metabolic unhealthy non-diabetes subtype), 5 (obesity and diabetes subtype), 6 (metabolic unhealthy non-obesity subtype), and 7 (mixed subtype).

RESULTS

Over the study period, the estimated prevalence of MAFLD increased significantly from 22% in 1988-1994 to 36% in 2017-2020. The prevalence of Type 4 was the highest, followed by that of Type 7, whereas other types were low and almost unchanged over time. Individuals with MAFLD had 19% and 38% increased mortality risks from all causes and cardiovascular disease, respectively. Among them, the metabolically unhealthy participants with normal weight demonstrated a 116% higher risk for all-cause mortality [hazard ratio (HR): 2.16, 95% CI: 1.52-3.08] and a 222% higher risk for cardiovascular mortality (HR: 3.22, 95% CI: 1.72-6.04). Interestingly, stratification and interaction analyses demonstrated a significant impact of metabolic parameters on the relationship between MAFLD and all-cause mortality.

CONCLUSIONS

In conclusion, our study identified an increase in MAFLD prevalence and a significant association between metabolic derangements in MAFLD and all-cause or cardiovascular mortality.

Для цитирования: Xie Zhi-Qin, Li Hong-Xia, Wang Bing-Kun, Yang Zhao-Ming, Zhang Zi-Yu, Tan Wen-Liang, Li Wen-Xin, Wang Qing-Bin, Yang Lei, Zhuang Hong-Kai, Tang Chen-Wei, Shang Chang-Zhen, Chen Ya-Jin. Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study.. European journal of internal medicine. 2023. DOI: 10.1016/j.ejim.2023.01.029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.